Novartis’ Entresto Labeling Expansion Bid Heads To US FDA Panel

 
• By Sue Sutter
  
Small narrow living room with space problems and a sofa between walls (3D Rendering)
The Entresto trial in heart failure patients with preserved ejection fraction narrowly missed its primary endpoint. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers